{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:00:34Z","timestamp":1760709634486,"version":"3.41.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:00:00Z","timestamp":1530144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Many countries have acquired antiviral stockpiles for pandemic influenza mitigation and a significant part of the stockpile may be focussed towards community-based treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We developed a spreadsheet-based, decision tree model to assess outcomes averted and cost-effectiveness of antiviral treatment for outpatient use from the perspective of the healthcare payer in the UK. We defined five pandemic scenarios\u2014one based on the 2009 A(H1N1) pandemic and four hypothetical scenarios varying in measures of transmissibility and severity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Community-based antiviral treatment was estimated to avert 14\u201323% of hospitalizations in an overall population of 62.28 million. Higher proportions of averted outcomes were seen in patients with high-risk conditions, when compared to non-high-risk patients. We found that antiviral treatment was cost-saving across pandemic scenarios for high-risk population groups, and cost-saving for the overall population in higher severity influenza pandemics. Antiviral effectiveness had the greatest influence on both the number of hospitalizations averted and on cost-effectiveness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This analysis shows that across pandemic scenarios, antiviral treatment can be cost-saving for population groups at high risk of influenza-related complications.<\/jats:p><\/jats:sec>","DOI":"10.1093\/pubmed\/fdy108","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T19:09:58Z","timestamp":1528484998000},"page":"379-390","source":"Crossref","is-referenced-by-count":2,"title":["Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness"],"prefix":"10.1093","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2093-5781","authenticated-orcid":false,"given":"Sudhir","family":"Venkatesan","sequence":"first","affiliation":[{"name":"Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Carias","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Biggerstaff","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela P","family":"Campbell","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan S","family":"Nguyen-Van-Tam","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Kahn","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puja R","family":"Myles","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin I","family":"Meltzer","sequence":"additional","affiliation":[{"name":"Centers for Disease Control and Prevention, Atlanta, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,6,28]]},"reference":[{"year":"2012","author":"DH Pandemic Influenza Preparedness Team","key":"2019071712161825900_fdy108C1"},{"volume-title":"Pandemic Influenza Preparedness and Response: A WHO Guidance Document","year":"2009","author":"Programme WHOGI","key":"2019071712161825900_fdy108C2"},{"year":"2017","author":"U.S. Department of Health and Human Services","key":"2019071712161825900_fdy108C3"},{"year":"2016","author":"Centers for Disease Control and Prevention","key":"2019071712161825900_fdy108C4"},{"issue":"2","key":"2019071712161825900_fdy108C5","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1086\/314904","article-title":"Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections","volume":"180","author":"Monto","year":"1999","journal-title":"J Infect Dis"},{"issue":"suppl_2","key":"2019071712161825900_fdy108C6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/jac\/44.suppl_2.23","article-title":"Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis","volume":"44","author":"Monto","year":"1999","journal-title":"J Antimicrob Chemother"},{"issue":"9218","key":"2019071712161825900_fdy108C7","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/S0140-6736(00)02288-1","article-title":"Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial","volume":"355","author":"Nicholson","year":"2000","journal-title":"Lancet"},{"issue":"8","key":"2019071712161825900_fdy108C8","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial","volume":"283","author":"Treanor","year":"2000","journal-title":"J Am Med Assoc"},{"issue":"5","key":"2019071712161825900_fdy108C9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/00006454-200005000-00005","article-title":"Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial","volume":"19","author":"Hedrick","year":"2000","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"2019071712161825900_fdy108C10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00006454-200102000-00002","article-title":"Oral oseltamivir treatment of influenza in children","volume":"20","author":"Whitley","year":"2001","journal-title":"Pediatr Infect Dis J"},{"issue":"8","key":"2019071712161825900_fdy108C11","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1086\/656408","article-title":"Early oseltamivir treatment of influenza in children 1\u20133 years of age: a randomized controlled trial","volume":"51","author":"Heinonen","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2019071712161825900_fdy108C12","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1473-3099(13)70267-6","article-title":"Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial","volume":"14","author":"Fry","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"2019071712161825900_fdy108C13","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1128\/AAC.01718-10","article-title":"Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients","volume":"55","author":"Kohno","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2019071712161825900_fdy108C14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3851\/IMP2874","article-title":"Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials","volume":"20","author":"Whitley","year":"2015","journal-title":"Antivir Ther"},{"issue":"27","key":"2019071712161825900_fdy108C15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2807\/1560-7917.ES2014.19.27.20850","article-title":"Evidence and policy for influenza control","volume":"19","author":"Kelly","year":"2014","journal-title":"Euro Surveill"},{"issue":"9941","key":"2019071712161825900_fdy108C16","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/S0140-6736(14)60726-1","article-title":"Antivirals for influenza: where now for clinical practice and pandemic preparedness?","volume":"384","author":"Nguyen-Van-Tam","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"2019071712161825900_fdy108C17","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008965.pub3","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children","volume":"1","author":"Jefferson","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"2019071712161825900_fdy108C18","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1001\/archinte.163.14.1667","article-title":"Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations","volume":"163","author":"Kaiser","year":"2003","journal-title":"Arch Intern Med"},{"issue":"9979","key":"2019071712161825900_fdy108C19","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(14)62449-1","article-title":"Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials","volume":"385","author":"Dobson","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"2019071712161825900_fdy108C20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1093\/fampra\/cms059","article-title":"Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials","volume":"30","author":"Ebell","year":"2012","journal-title":"Fam Pract"},{"key":"2019071712161825900_fdy108C21","doi-asserted-by":"crossref","first-page":"g2545","DOI":"10.1136\/bmj.g2545","article-title":"Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments","volume":"348","author":"Jefferson","year":"2014","journal-title":"Br Med J"},{"year":"2007","author":"Department of Health","key":"2019071712161825900_fdy108C22"},{"issue":"2","key":"2019071712161825900_fdy108C23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3201\/eid1402.070478","article-title":"Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic","volume":"14","author":"Siddiqui","year":"2008","journal-title":"Emerg Infect Dis"},{"issue":"62","key":"2019071712161825900_fdy108C24","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1098\/rsif.2010.0715","article-title":"Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective","volume":"8","author":"Carrasco","year":"2011","journal-title":"J R Soc Interface"},{"issue":"8","key":"2019071712161825900_fdy108C25","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3201\/eid1108.041156","article-title":"Cost-benefit of stockpiling drugs for influenza pandemic","volume":"11","author":"Balicer","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"2019071712161825900_fdy108C26","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2471\/BLT.12.109025","article-title":"Cost-effectiveness analysis of pandemic influenza preparedness: what\u2019s missing?","volume":"90","author":"Drake","year":"2012","journal-title":"Bull World Health Organ"},{"issue":"1","key":"2019071712161825900_fdy108C27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3201\/eid1901.120124","article-title":"Novel framework for assessing epidemiologic effects of influenza epidemics and pandemics","volume":"19","author":"Reed","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"suppl_1","key":"2019071712161825900_fdy108C28","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/cid\/civ088","article-title":"Standardizing scenarios to assess the need to respond to an influenza pandemic","volume":"60","author":"Meltzer","year":"2015","journal-title":"Clin Infect Dis"},{"volume-title":"Pandemic (H1N1) 2009 in England; An Overview of Initial Epidemiological Findings and Implications for the Second Wave","year":"2009","author":"Health Protection Agency","key":"2019071712161825900_fdy108C29"},{"year":"2015","author":"Academy of Medical Sciences, Wellcome Trust","key":"2019071712161825900_fdy108C30"},{"issue":"suppl_1","key":"2019071712161825900_fdy108C31","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1093\/cid\/civ084","article-title":"Estimating the United States demand for influenza antivirals and the effect on severe influenza disease during a potential pandemic","volume":"60","author":"O\u2019Hagan","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2019071712161825900_fdy108C32","doi-asserted-by":"crossref","first-page":"e004174","DOI":"10.1136\/bmjopen-2013-004174","article-title":"Access to the NHS by telephone and Internet during an influenza pandemic: an observational study","volume":"4","author":"Rutter","year":"2014","journal-title":"BMJ Open"},{"year":"2011","author":"Department of Health","key":"2019071712161825900_fdy108C33"},{"year":"2017","author":"Curtis","key":"2019071712161825900_fdy108C34"},{"year":"2017","author":"World Bank","key":"2019071712161825900_fdy108C35"},{"issue":"1","key":"2019071712161825900_fdy108C36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/bmb\/ldq033","article-title":"Health outcomes in economic evaluation: the QALY and utilities","volume":"96","author":"Whitehead","year":"2010","journal-title":"Br Med Bull"},{"issue":"5","key":"2019071712161825900_fdy108C37","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hec.1485","article-title":"Dynamic versus static models in cost\u2010effectiveness analyses of anti\u2010viral drug therapy to mitigate an influenza pandemic","volume":"19","author":"Lugn\u00e9r","year":"2010","journal-title":"Health Econ"},{"year":"2013","author":"Public Accounts Committee","key":"2019071712161825900_fdy108C38"},{"issue":"10","key":"2019071712161825900_fdy108C39","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/cix127","article-title":"Impact of outpatient neuraminidase inhibitor treatment in patients infected with influenza A(H1N1)pdm09 at high risk of hospitalization: an individual participant data metaanalysis","volume":"64","author":"Venkatesan","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2019071712161825900_fdy108C40","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/jac\/dkt496","article-title":"Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada","volume":"69","author":"Marra","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2019071712161825900_fdy108C41","doi-asserted-by":"crossref","first-page":"RRN1130","DOI":"10.1371\/currents.RRN1130","article-title":"The early transmission dynamics of H1N1pdm influenza in the United Kingdom","volume":"1","author":"Ghani","year":"2010","journal-title":"PLoS Curr"},{"year":"2017","author":"Electronic Medicines Compendium (eMC)","key":"2019071712161825900_fdy108C42"},{"issue":"5","key":"2019071712161825900_fdy108C43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S2213-2600(14)70041-4","article-title":"Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data","volume":"2","author":"Muthuri","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"3","key":"2019071712161825900_fdy108C44","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/irv.12363","article-title":"Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis","volume":"10","author":"Muthuri","year":"2016","journal-title":"Influenza Other Respir Viruses"},{"year":"2017","author":"Watson","key":"2019071712161825900_fdy108C45"},{"year":"2011","author":"Department of Health","key":"2019071712161825900_fdy108C46"},{"issue":"1","key":"2019071712161825900_fdy108C47","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1471-2334-11-68","article-title":"Using an online survey of healthcare-seeking behaviour to estimate the magnitude and severity of the 2009 H1N1v influenza epidemic in England","volume":"11","author":"Brooks-Pollock","year":"2011","journal-title":"BMC Infect Dis"},{"issue":"4","key":"2019071712161825900_fdy108C48","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/infdis\/jiu224","article-title":"Influenza-like illness, the time to seek healthcare, and influenza antiviral receipt during the 2010\u20132011 influenza season\u2014United States","volume":"210","author":"Biggerstaff","year":"2014","journal-title":"J Infect Dis"},{"year":"2017","author":"Public Health England","key":"2019071712161825900_fdy108C49"},{"year":"2010","author":"Hine","key":"2019071712161825900_fdy108C50"},{"issue":"8","key":"2019071712161825900_fdy108C51","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/thoraxjnl-2011-200266","article-title":"Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A\/H1N1 pandemic 2009\u20132010 in the UK","volume":"67","author":"Myles","year":"2012","journal-title":"Thorax"},{"volume-title":"Unit Costs of Health and Social Care 2008","year":"2009","author":"Curtis","key":"2019071712161825900_fdy108C52"},{"year":"2009","author":"British Medical Association and the Royal Pharmaceutical Society of Great Britain","key":"2019071712161825900_fdy108C53"},{"year":"2008","author":"Department of Health","key":"2019071712161825900_fdy108C54"},{"issue":"12","key":"2019071712161825900_fdy108C55","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/j.vaccine.2010.01.002","article-title":"Vaccination against pandemic influenza A\/H1N1v in England: a real-time economic evaluation","volume":"28","author":"Baguelin","year":"2010","journal-title":"Vaccine"}],"container-title":["Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jpubhealth\/article-pdf\/41\/2\/379\/28943205\/fdy108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T01:44:40Z","timestamp":1751679880000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpubhealth\/article\/41\/2\/379\/5046089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,28]]},"references-count":55,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,6,28]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/pubmed\/fdy108","relation":{},"ISSN":["1741-3842","1741-3850"],"issn-type":[{"type":"print","value":"1741-3842"},{"type":"electronic","value":"1741-3850"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2018,6,28]]}}}